Status:
UNKNOWN
Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management
Lead Sponsor:
University of Baghdad
Conditions:
Covid-19
SARS Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Assessment of the Effectiveness of Niclosamide as Add on Therapy to the Standard of care Measures in COVID-19 Management in a randomized controlled clinical trial
Detailed Description
Protocol of therapy Niclosamaide Add on group * NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first ...
Eligibility Criteria
Inclusion
- Patients with age above 18 years and of any gender.
- Definite diagnosis of COVID-19 according to the WHO classification criteria ( 18).
- Patients symptomatic for no more than three days for mild-moderate cases, no more than two days after being severe cases, and no more than one day after being critical cases.
- Understands and agrees to comply with planned study procedures.
Exclusion
- Patients refuse to enrol in the study
- Patients with hypersensitivity or severe adverse effects to niclosamide
- Renal impairment
- Hepatic impairment
- Pregnancy or a desire to become pregnant
- Breast feeding
Key Trial Info
Start Date :
January 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 3 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04753619
Start Date
January 3 2021
End Date
December 3 2021
Last Update
June 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmed S. Abdulamir
Baghdad, Baghdada, Iraq, 00964